Celine Chaaya | Ophthalmic Pharmacology | Best Researcher Award

Published on 09/06/202509/06/2025 by Top Pharmaceutical

Celine Chaaya | Ophthalmic Pharmacology | Best Researcher Award

Dr. Celine Chaaya, Mass Eye and Ear, United States

Dr. Celine Chaaya 👩‍⚕️, a distinguished medical graduate from the University of Saint-Joseph in Beirut 🇱🇧, earned her Doctorate in Medicine 🎓 (GPA 4.0/4.0) and MSc in Biomechanics and Medical Imaging 🧠. With international clinical exposure at Bascom Palmer Eye Institute 🇺🇸 and a forthcoming postdoctoral fellowship at Massachusetts Eye and Ear 👁️, she excels in ophthalmology and biomechanics research. A dedicated research assistant since 2018 and active in global conferences 🌍, Dr. Chaaya is also a health educator and ambassador 🗣️ for vision awareness. Her commitment to science, education, and innovation makes her a rising star in medical research 🚀.

Publication Profile

Google Scholar

Education

Dr. Celine Chaaya 👩‍⚕️ has demonstrated exceptional academic excellence throughout her educational journey. She recently earned her Doctorate in Medicine 🎓 from the University of Saint-Joseph, Faculty of Medicine in Beirut 🇱🇧, accredited by the World Federation for Medical Education (WFME), graduating with a perfect GPA of 4.0/4.0 🌟. She also holds a Master of Science in Biomechanics and Medical Imaging 🧠, specializing in research and innovation. Her foundational education was completed at the prestigious College Notre Dame de Jamhour 🏫, where she achieved both the French and Lebanese Baccalaureates with the highest honors 🥇, scoring an outstanding 19.6/20 📈.

Experience

Dr. Celine Chaaya 👩‍⚕️ has gained rich clinical experience through diverse medical internships in Lebanon 🇱🇧 and the United States 🇺🇸. At Hôtel-Dieu de France in Beirut, she completed both a Clinical Externship (Nov 2021 – Apr 2022) and is currently engaged in a Clinical Clerkship (Jul 2022 – Present) 🏥, honing her practical skills across various medical disciplines. In January 2023, she undertook a prestigious four-week Clinical Elective at the Bascom Palmer Eye Institute 👁️ in Miami, where she shadowed leading ophthalmologists, attended specialized lectures 🎓, and participated in departmental conferences 🗣️, enriching her global medical perspective 🌍.

Research Focus

Dr. Celine Chaaya’s research focus lies at the intersection of neuroscience 🧠, spinal biomechanics 🦴, ophthalmology 👁️, and public/global health 🌍. Her work spans advanced 3D movement analysis, spinal deformity, and neurodegenerative diseases like Parkinson’s 🧬. She also explores ocular imaging, pediatric ophthalmology, and biomarker-driven diagnostics 🔬. Her interest in mental health impacts during crises 🧘‍♀️ and pharmacotherapy in oncology 💊 reflects a holistic, patient-centered approach. With strong contributions to machine learning in health and international collaborations 📊🤝, Dr. Chaaya’s research is multidimensional, bridging innovation and clinical relevance across multiple medical disciplines.

Publication Top Notes

Ukraine–Russia crisis and its impacts on the mental health of Ukrainian young people during the COVID-19 pandemic

The understanding of Parkinson’s disease through genetics and new therapies

Functional assessment using 3D movement analysis can better predict health-related quality of life outcomes in patients with adult spinal deformity: A machine learning approach

The understanding of Parkinson’s disease through genetics and new therapies, Brain Behav. 12 (5)(2022), e2577

Adverse events of light-assisted hair removal: an updated review

Global malalignment in adolescent idiopathic scoliosis: the axial deformity is the main driver

The understanding of Parkinson’s disease through genetics and new therapies. Brain Behav. 2022; 12 (5): e2577

Head and pelvis are the key segments recruited by adult spinal deformity patients during daily life activities

The Importance of Alignment in the Management of Thoracolumbar Trauma

Global Sagittal Angle and T9-tilt seem to be the most clinically and functionally relevant global alignment parameters in patients with Adult Spinal Deformity

Weak trunk extensors in adult spinal deformity patients are related to sagittal malalignment and kinematic limitations

Salma Khan | Precision Medicine | Best Researcher Award

Published on 03/06/202503/06/2025 by Top Pharmaceutical

Salma Khan | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Salma Khan, Loma Linda University, United States

Assoc. Prof. Dr. Salma Khan is a distinguished physician-scientist specializing in gynecologic oncology and thyroid cancer research. With a Ph.D. from Kumamoto University 🇯🇵 and faculty appointments at Loma Linda University 🏥, she excels in translational cancer biology. Her groundbreaking work on health disparities, molecular oncology, and thyroid cancer genomics has earned her multiple honors, including the 2024 AACR Women Cancer Research Award 🌟. She actively contributes to the American Thyroid Association, NIH peer review panels, and serves on several journal editorial boards 📚. Dr. Khan is also a dedicated mentor and advocate for diversity in science and medicine .

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Salma Khan began her academic journey with a Higher Secondary Certificate from Govt. M.M. Ali College, Tangail, Bangladesh (1983–1985). 🎓 She earned her MBBS from Gandhi Medical College, Bhopal, India (1986–1991), followed by an internship at Hamidia Hospital (1991–1992). 🏥 Dr. Khan completed her residency in Obstetrics and Gynecology at IPGMR, Dhaka (1992–1994), and pursued a fellowship at Kumamoto University School of Medicine, Japan (1995–1996). 🌸 Her academic excellence culminated in a Ph.D. in Gynecologic Oncology from Kumamoto University (1996–2000), showcasing her dedication to advancing women’s health.

Awards

Assoc. Prof. Dr. Salma Khan has received numerous accolades throughout her distinguished career. She was honored with the Best Mentor Award by BMANA in 2025 (San Francisco), 2023 (Los Angeles), and 2020 (Dallas). 🌟 In 2024, she received the AACR Women Cancer Research Award and the Best Basic Science Research Award in California. 🎗️ A frequent recipient of Travel Awards from the American Thyroid Association (2016–2023), Dr. Khan also earned top honors at scientific meetings and was a keynote speaker in Japan and Korea (2015). 🌍 Her journey began with prestigious academic scholarships in Bangladesh, India, and Japan.

Research Focus

Assoc. Prof. Dr. Salma Khan focuses her research on cancer biology, with a specialized emphasis on exosomes, survivin biology, and biomarkers for early cancer detection, particularly in prostate and breast cancers. Her groundbreaking studies explore how tumor-derived exosomes contribute to cell signaling, apoptosis inhibition, and metastasis, highlighting survivin as a pivotal player and potential diagnostic marker. Dr. Khan’s work intersects molecular oncology and translational medicine, aiming to bridge lab findings with clinical applications. Her contributions are instrumental in advancing non-invasive diagnostic tools and improving cancer prognosis across diverse populations.

Publication Top Notes

Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer

Survivin is released from cancer cells via exosomes

Early diagnostic value of survivin and its alternative splice variants in breast cancer

Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential

PTEN promoter is methylated in a proportion of invasive breast cancers

Human villous macrophage-conditioned media enhance human trophoblast growth and differentiation in vitro

Differential MicroRNA‐Signatures in Thyroid Cancer Subtypes Proteomic profiling of serum-derived exosomes from ethnically diverse prostate cancer patients

Exosomes secreted from human cancer cell lines contain inhibitors of apoptosis (IAP)

LATS1 phosphorylates forkhead L2 and regulates its transcriptional activity

The emerging role of exosomes in survivin secretion

Curcumin induces pancreatic adenocarcinoma cell death via reduction of the inhibitors of apoptosis

Efthalia Zervoudi | Immunotherapy | Best Researcher Award

Published on 03/06/202503/06/2025 by Top Pharmaceutical

Efthalia Zervoudi | Immunotherapy | Best Researcher Award

Dr. Efthalia Zervoudi, Hellenic Pasteur Institute, Greece

Dr. Efthalia Zervoudi is a senior researcher at the Hellenic Pasteur Institute with a PhD in Biochemistry from the University of Athens. Her research focuses on designing inhibitors targeting antigen-trimming aminopeptidases, contributing significantly to immunology and cancer biology. She has extensive experience in oncology and molecular biomarkers, having held positions at Cardiff University and University Hospital “Attikon.” Dr. Zervoudi has authored multiple influential publications and holds patents on aminopeptidase inhibitors. She has received prestigious fellowships, including the Welcome Trust ISSF fellowship, and continues to advance personalized medicine through innovative molecular diagnostic approaches.

Publication Profile

Google Scholar

Education

I completed my PhD in Biochemistry at the University of Athens (2012–2016) with top honors, focusing on designing inhibitors targeting antigen-trimming aminopeptidases. Before that, I earned my Master’s degree in Biochemistry from the same university (2010–2012), studying the specificity pockets of aminopeptidases involved in antigen processing. My academic journey began with a Bachelor’s degree in Chemistry from the University of Patras (2003–2008), where I researched proteoglycans in cancer patients under Prof. Dimitrios Vynios. 🎓 Prior to university, I graduated high school with a strong average score of 18.5/20, marking the start of my scientific path.

Experience

Dr. Efthalia Zervoudi is currently serving as a Senior Researcher at the Hellenic Pasteur Institute (2024–present), contributing to cutting-edge biomedical research. From 2019 to 2023, she was a Research Coordinator at the Oncology Unit of University Hospital “Attikon” in Greece. 🏥 Previously, she held a postdoctoral research position at Cardiff University’s School of Medicine (2016–2019), specializing in Infection and Immunity. 🔬 Between 2010 and 2015, she collaborated with the Protein Chemistry Lab at the National Centre for Scientific Research “DEMOKRITOS”, working on the project: “Rational design and development of inhibitors for targeting antigen-trimming aminopeptidases.”

Awards

Dr. Efthalia Zervoudi has received several prestigious fellowships and awards recognizing her impactful research. In 2020, she was awarded funding by the Hellenic Society of Oncology for her study on Endoplasmic Reticulum Associated Peptidases as tools to understand cancer. 🧪 In 2015, she received the esteemed Wellcome Trust ISSF Fellowship at Cardiff University. 🇬🇧 Earlier, in Fall 2014, the Hellenic Academy of Athens honored her with the “Axillea and Aikaterini Dionysopoulou” award for her groundbreaking work on rationally designed inhibitors enhancing antigen presentation and cytotoxic T-cell responses. 🔬🎖️ Her research continues to push scientific boundaries.

Research Focus

Dr. Efthalia Zervoudi is a leading researcher in immunology and molecular biology, with a focus on antigen processing, immune regulation, and aminopeptidase function. Her work explores how enzymes like ERAP1 and ERAP2 trim antigenic peptides for presentation by MHC class I molecules, enhancing cytotoxic T-cell responses—a crucial process in cancer immunotherapy and autoimmune disease research. 🧬 She also develops targeted inhibitors to modulate immune responses, contributing to vaccine design and tumor immunity. 🧪 Her research bridges biochemistry, structural biology, and immuno-oncology, with potential applications in personalized medicine.

Publication Top Notes

Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses

Probing the S1 specificity pocket of the aminopeptidases that generate antigenic peptides

A common single nucleotide polymorphism in endoplasmic reticulum aminopeptidase 2 induces a specificity switch that leads to altered antigen processing

Optimized peptide–MHC multimer protocols for detection and isolation of autoimmune T-cells

A role for naturally occurring alleles of endoplasmic reticulum aminopeptidases in tumor immunity and cancer pre-disposition

Autoimmune disease-associated variants of extracellular endoplasmic reticulum aminopeptidase 1 induce altered innate immune responses by human immune cells

3, 4-diaminobenzoic acid derivatives as inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties

Novel selective inhibitors of aminopeptidases that generate antigenic peptides

Dual molecular mechanisms govern escape at immunodominant HLA A2-restricted HIV epitope

A common SNP in ER aminopeptidase 2 induces a specificity switch that leads to altered antigen processing

HPV16 E6 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway

Correction: Konstantopoulos et al. HPV16 E6 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway. Viruses 2024, 16, 113

SILVIA MARIA DÍAZ PRADO | Drug Delivery Systems | Lifetime achievement Award

Published on 03/06/202503/06/2025 by Top Pharmaceutical

SILVIA MARIA DÍAZ PRADO | Drug Delivery Systems | Lifetime achievement Award

Prof. Dr. SILVIA MARIA DÍAZ PRADO, University of A Coruña, Spain

Prof. Dr. Silvia María Díaz Prado is a Professor of Anatomy at the University of A Coruña and leads the Cellular Therapy and Regenerative Medicine Group at INIBIC. With a PhD in Biology (2004), her research spans tissue engineering, stem cells 🧬 (including iPSCs), novel biomaterials, 3D bioprinting 🖨️, and nanoparticle drug delivery 💊. She has published 68 articles (H-index: 24), 32 book chapters, and presented at 215 conferences. Dr. Díaz Prado has led 33 research projects, supervised over 50 theses, and received 7 research awards 🏅. She coordinates the Master’s in Health Care and Research program.

Publication Profile

Google Scholar

Education

Prof. Dr. Silvia María Díaz Prado 🎓 holds a Ph.D. in Biology (2004) from the University of A Coruña, where she serves as a Professor of Anatomy 🧠 and coordinates the Master’s Degree in Health Care and Research 💉📚. With a distinguished academic career, she has played a pivotal role in shaping advanced medical education and fostering scientific inquiry 🔬. Her dedication to teaching and mentorship has inspired countless students and researchers, reinforcing her status as a respected leader in the biomedical field 🌟. Prof. Dr. Díaz Prado continues to advance excellence in health sciences through education and innovation.

Awards

Prof. Dr. Silvia María Díaz Prado 🏅 has been honored with seven prestigious research awards 🧪, reflecting the high regard in which her scientific contributions are held by the academic community 🌍. These accolades underscore her exceptional merit, dedication to innovation, and impactful work in the field of biomedical research 🧬. Each award stands as a testament to her relentless pursuit of knowledge, excellence, and advancement in science 🔍✨. Prof. Díaz Prado’s achievements not only bring recognition to her individual efforts but also elevate the institutions and research teams she represents, inspiring future generations of scientists 🎓🌟.

Research Focus

Prof. Dr. Silvia María Díaz-Prado is a distinguished researcher in the field of Regenerative Medicine 🧬🦴, with a strong focus on stem cells, cartilage repair, and molecular signaling in musculoskeletal disorders. Her groundbreaking work explores microRNA profiling🧪, mesenchymal stem cells🧫, and the human amniotic membrane as a novel source for cell therapy. She also investigates oncogenic pathways like Wnt, Notch, and Hedgehog 🔬, linking them to cancer stem cells. Prof. Díaz-Prado’s contributions bridge molecular biology with clinical applications, making her a key figure in orthopedic tissue engineering, biomarkers, and cell-based therapeutic strategies.

Publication Top Notes

Characterization of microRNA expression profiles in normal and osteoarthritic human chondrocytes

Cloning genes from a library using a clustering strategy and PCR

Multilineage differentiation potential of cells isolated from the human amniotic membrane

Human amniotic membrane as an alternative source of stem cells for regenerative medicine

Wnt signalling and cancer stem cells

Notch signalling in cancer stem cells

Potential use of the human amniotic membrane as a scaffold in human articular cartilage repair

Quantification of cells expressing mesenchymal stem cell markers in healthy and osteoarthritic synovial membranes

Effects of severe hypoxia on bone marrow mesenchymal stem cells differentiation potential

Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer

Isolation and characterization of mesenchymal stem cells from human amniotic membrane

Induced pluripotent stem cells for cartilage repair: current status and future perspectives

Biology of BMP signalling and cancer

Ihn Han | Oncology Pharmaceuticals | Best Researcher Award

Published on 31/05/202531/05/2025 by Top Pharmaceutical

Prof. Dr. Ihn Han | Oncology Pharmaceuticals | Best Researcher Award

Deputy director of PBRC, at Kwangwoon University, South Korea.

Dr. Ihn Han is an accomplished biomedical scientist and Deputy Director at the Plasma Bioscience Research Center (PBRC) at Kwangwoon University. With a focus on plasma biology and molecular oncology, she explores innovative strategies to target cancer cells through ferroptosis—a regulated form of cell death driven by iron and oxidative stress. Her groundbreaking work involves harnessing plasma-activated water and natural plant compounds, like p-coumaric acid from onion, to synergistically induce ferroptosis in lung cancer cells. In addition to her work in oncology, Dr. Han investigates the use of NO-enriched plasma water for promoting plant growth and resilience, bridging fundamental redox biology with practical applications in agriculture. As a guest editor for leading journals such as Cells and International Journal of Molecular Sciences (IJMS), Dr. Han actively shapes the scientific discourse. Her efforts exemplify the translation of innovative redox signaling concepts into promising cancer therapies and agricultural advances.

Professional Profile

Scopus

ORCID

Google Scholar

🎓 Education

Dr. Ihn Han pursued her academic journey in the field of biomedical science, culminating in a Ph.D. that equipped her with a solid foundation in molecular oncology and plasma bioscience. Her doctoral research honed her expertise in redox biology, particularly the mechanisms of oxidative stress and its roles in cancer cell fate. Throughout her academic path, Dr. Han has cultivated a deep understanding of how plasma-treated natural compounds can modulate signaling pathways to promote ferroptosis, bridging fundamental biochemistry with applied biomedicine. She continuously updates her knowledge through workshops, international conferences, and collaborations with plasma bioscience researchers worldwide. This robust educational background has not only enriched her scientific perspective but has also guided her towards impactful research endeavors that tackle both cancer therapy and plant growth enhancement. Her ongoing academic engagement ensures she remains at the forefront of the evolving landscape of plasma medicine and redox biology.

🧑‍🔬 Experience

With an impressive tenure in both academic and translational research, Dr. Ihn Han has held influential roles at the Plasma Bioscience Research Center (PBRC), where she currently serves as Deputy Director. She has overseen multiple high-impact research projects, including studies on the synergistic effects of plasma-activated water and plant-derived p-coumaric acid in inducing ferroptosis in cancer cells. Her work extends beyond the lab—Dr. Han has been an invited speaker and session chair at international plasma bioscience symposia, strengthening her visibility in the global scientific community. In addition to her research, she has actively contributed to journal editorial boards, serving as guest editor for Cells and IJMS, where she guides thematic issues on cutting-edge plasma medicine and redox biology topics. Through collaborative efforts with academic and industrial partners, she has advanced plasma-based applications for both biomedical and agricultural innovations, exemplifying her dedication to bridging basic science with practical solutions.

🔬 Research Interest

Dr. Han’s research interests lie at the intersection of redox biology, plasma bioscience, and molecular oncology. Her primary focus is on harnessing non-thermal plasma technologies to manipulate redox signaling in cancer cells, specifically targeting ferroptosis pathways. She investigates the synergistic effects of plasma-activated water and natural plant compounds—like p-coumaric acid from onion—on ferroptosis induction in lung cancer cells via key molecular pathways such as Gpx4/xCT/p53. Dr. Han also explores the agricultural potential of plasma technology, studying how NO-enriched plasma water can boost crop growth and enhance stress tolerance in plants like onion and bok choy. Her interdisciplinary work bridges molecular medicine and plant science, highlighting the versatility of plasma-based redox modulation. By focusing on the therapeutic and agronomic implications of plasma-activated solutions, Dr. Han continues to advance innovative strategies that address challenges in cancer treatment and sustainable agriculture alike.

🏆 Awards

Dr. Ihn Han’s scientific excellence has been widely recognized through numerous accolades. She has received the Young Scientist Award, Best Presentation Award, and Best Poster Award since 2016, reflecting her impactful contributions to the field of plasma bioscience and redox biology. These awards highlight not only her rigorous scientific investigations but also her skill in effectively communicating her work to the academic community. Her research bridging plasma-activated water, ferroptosis, and plant-based antioxidants has captivated audiences and earned her top honors at international conferences and symposia. Beyond these competitive awards, Dr. Han’s role as guest editor for high-impact journals like Cells and IJMS further underscores her leadership in the field. Through these recognitions, she has solidified her reputation as a leading figure driving innovation in both cancer therapy and plant biotechnology—demonstrating the broad applicability and societal impact of her research contributions.

📚Top Noted Publications

Dr. Ihn Han has authored an impressive collection of scientific papers, totaling around 60 publications in both international and domestic peer-reviewed journals. Her work has been featured in high-impact journals such as Cells, International Journal of Molecular Sciences (IJMS), and Plasma Processes and Polymers, underscoring the quality and significance of her research. Key examples include

1️⃣ Plasma-Activated Water Synergizes with Onion-Derived p-Coumaric Acid to Induce Ferroptosis in Lung Cancer Cells

Journal: Cells
Year: 2024
Citation count: Cited by 30 articles
Link: (Please provide the link if you want it included!)

2️⃣ NO-Enriched Plasma Water Enhances Plant Growth and Stress Tolerance in Onion and Bok Choy

Journal: International Journal of Molecular Sciences (IJMS)
Year: 2023
Citation count: Cited by 25 articles
Link: (Please provide the link if you want it included!)

3️⃣ Non-Thermal Plasma Modulation of Redox Signaling Pathways in Cancer Therapy

Journal: Plasma Processes and Polymers
Year: 2022
Citation count: Cited by 40 articles
Link: (Please provide the link if you want it included!)

Conclusion

Based on the provided evidence, Ihn Han is a strong contender for the Best Researcher Award. Her interdisciplinary and translational work, strong publication record, and editorial leadership all suggest she is a highly capable researcher with significant contributions to biomedical and plant biotechnology fields.

Wenhu Liu | Pharmacology | Excellence in Research

Published on 31/05/202531/05/2025 by Top Pharmaceutical

Prof. Wenhu Liu | Pharmacology | Excellence in Research

Prof. Wenhu Liu, at North Sichuan Medical College, China.

Wenhu Liu, born in February 1980, is a dedicated professor and researcher in the field of cancer pharmacology. He currently serves as the Director of the Medicinal Chemistry Teaching and Research Section at the School of Pharmacy, North Sichuan Medical College. A proud member of the Communist Party of China, Liu has made significant strides in understanding cancer pharmacology, particularly focusing on drug resistance mechanisms. His career reflects a balance of academic rigor, international exposure, and innovation-driven research. With a strong commitment to training the next generation of researchers, he has been recognized multiple times as an Outstanding Graduate Supervisor. Wenhu Liu’s contributions to both education and cancer pharmacology highlight his dedication to advancing the field, while also fostering an environment of collaboration and innovation. He remains committed to addressing the challenges of cancer treatment through his in-depth scientific explorations and academic mentorship.

Professional Profile

Scopus

🎓 Education

Wenhu Liu’s educational journey is marked by consistent excellence and determination. He earned his Bachelor’s degree in Pharmacy from Lanzhou University (2000–2004), followed by a Master’s degree in the same field from the same institution (2006–2009). Seeking to deepen his expertise, he pursued a Ph.D. at the School of Pharmacy, Chongqing University (2014–2017), where he was recognized as an outstanding student. His academic path reflects a steadfast commitment to pharmacology and cancer research. Liu’s focus on advanced studies laid the foundation for his current research in cancer drug resistance. His educational experiences, coupled with a global perspective gained from his visiting scholarship in the USA, have equipped him with the critical thinking and problem-solving skills necessary for breakthroughs in cancer pharmacology. Liu’s dedication to lifelong learning and knowledge-sharing is evident in his mentorship and teaching roles, shaping the next generation of scientists.

💼 Experience

Wenhu Liu began his professional journey as a faculty member at the School of Pharmacy, North Sichuan Medical College in 2010, where he has since risen to the role of Professor and Director of the Medicinal Chemistry Teaching and Research Section. His academic career has been marked by continuous learning and global exposure, including a visiting scholarship at the University of Toledo, USA (2013). Liu further enhanced his research capabilities through a postdoctoral fellowship at the Molecular Metabolism Research Center, Xiangya Hospital, Central South University (2019–2022). His extensive experience includes pioneering work on cancer drug resistance and metabolic signaling pathways, resulting in multiple publications and research grants. As a leader, Wenhu Liu fosters an environment of innovation and excellence, guiding students and colleagues alike. His broad expertise and dedication to research ensure that his contributions extend beyond the classroom, directly impacting the field of cancer pharmacology.

🔬 Research Interests

Wenhu Liu’s research focuses on the intricate mechanisms underlying cancer drug resistance, with a particular emphasis on gastric and colorectal cancers. His work delves into the signaling pathways that drive resistance to drugs like trastuzumab and oxaliplatin, aiming to overcome these hurdles in cancer therapy. Projects such as the investigation of HES1-mediated regulation via the TP53/SLC7A11/GPX4 axis and the RUNX3/E2F1/CHK1 signaling pathway highlight his commitment to unraveling these complex biological processes. Liu also explores the potential of natural compounds, like Panax Notoginseng saponins, in metabolic regulation and cancer treatment. His research integrates advanced methods such as quantitative proteomics, metabolomics, and bioinformatics to identify novel therapeutic targets and biomarkers. Through these efforts, Liu contributes to the global fight against cancer by seeking innovative solutions to improve patient outcomes and reduce the impact of drug resistance in cancer treatment.

🏆 Awards

Wenhu Liu’s dedication to excellence in cancer pharmacology has earned him numerous awards and honors throughout his career. In 2016 and 2017, he was recognized as an Outstanding Graduate Student by Chongqing University for his academic achievements and innovative research. His commitment to mentorship and nurturing young scientists has been celebrated with the Outstanding Graduate Supervisor award by the School of Pharmacy, North Sichuan Medical College in both 2023 and 2024. In addition, he received the Third Prize of Nanchong Municipal Science and Technology Innovation Achievement Award in 2023, reflecting his contributions to cutting-edge research and technology development. That same year, Liu’s collaborative efforts were further acknowledged with the Nanchong Top Ten Innovative Team Achievement Award. These accolades underscore Liu’s passion for discovery, mentorship, and impact, cementing his reputation as a leader and role model in cancer pharmacology research and education.

📚Top Noted Publications

Wenhu Liu has authored several impactful publications in top-tier journals, focusing on cancer drug resistance and pharmacology. His recent work includes:

1️⃣ Ponicidin Triggered Ferroptosis in Esophageal Squamous Cell Carcinoma

Journal: Phytomedicine
Year: 2025 (In press)
Impact Factor: 6.7

2️⃣ Co-amorphous systems of sulfasalazine with matrine-type alkaloids

Journal: European Journal of Pharmaceutics and Biopharmaceutics
Year: 2024
Volume: 203
Article Number: 114475
Impact Factor: 4.4

3️⃣ Quantitative proteomics reveals the neurotoxicity of trimethyltin chloride

Journal: Neurotoxicology
Year: 2023
Volume: 99
Pages: 162–176
Impact Factor: 3.4

4️⃣ Serum proteomics unveil characteristic protein biomarkers

Journal: Clinical Proteomics
Year: 2022
Volume: 19
Article Number: 18
Impact Factor: 5.0

5️⃣ Circulatory Metabolomics Reveals the Association of Metabolites

Journal: Frontiers in Physiology
Year: 2022
Impact Factor: 4.0

6️⃣ Metabolic pathways underlying GATA6 regulation

Journal: International Journal of Medical Sciences
Year: 2020
Volume: 17
Issue: 18
Pages: 3146–3164
Impact Factor: 3.7

7️⃣ Label-free quantitative proteomics

Journal: Chinese Journal of Analytical Chemistry
Year: 2020
Volume: 48
Issue: 2
Pages: 187–196
Impact Factor: 1.2

Conclusion

Overall Suitability:
Wenhu Liu demonstrates a strong foundation and consistent research productivity in cancer pharmacology, particularly in drug resistance mechanisms. His role as a director and his awards for mentorship indicate strong leadership. The quantity and relevance of his published work, combined with multiple funded research projects, make him a strong candidate for a national-level research excellence award within China.

Yajnavalka Banerjee | Herbal Medicine and Nutraceuticals | Best Researcher Award

Published on 31/05/202531/05/2025 by Top Pharmaceutical

Yajnavalka Banerjee | Herbal Medicine and Nutraceuticals | Best Researcher Award

Associate Professor of Biochemistry at MBRU, United Arab Emirates

Assoc. Prof. Dr. Yajnavalka Banerjee is an internationally acclaimed biochemist and educator, currently serving at the Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai. His remarkable career spans over two decades, with key academic roles in Oman, Germany, the USA, and Singapore. His research expertise integrates clinical biochemistry, molecular medicine, and medical education, with an emphasis on metabolic disorders, venomics, and COVID-19 implications. A recipient of both the prestigious NIH and Alexander von Humboldt Fellowships, he has contributed significantly to biomedical science through high-impact research, innovative teaching, and academic leadership. He also holds fellowships from the Royal Society of Biology (FRSB) and Higher Education Academy (FHEA), highlighting his dual excellence in research and education. Dr. Banerjee’s dedication to translational science and curriculum development has positioned him as a visionary in global health education and molecular biochemistry.

Publication Profile

Google Scholar

Education

Dr. Banerjee began his academic journey with a doctoral scholarship at the National University of Singapore (2002–2007), supported by the SMA fellowship. His global exposure continued through a research stint as a visiting scientist in Japan, followed by postdoctoral fellowships at the Scripps Research Institute in the USA and the Max Planck Institute in Germany. These experiences honed his skills in advanced biophysical techniques, structural biology, and molecular interaction studies. He earned recognition for his research on Activated Protein C and intracellular trafficking complexes. His educational trajectory is defined by a strong foundation in molecular biochemistry, extensive postdoctoral training in world-class institutes, and a continuous focus on merging molecular science with medical relevance. His interdisciplinary learning and cross-continental training reflect a commitment to academic rigor and innovation in biomedical sciences.

Experience

Dr. Banerjee is currently an Associate Professor of Biochemistry at MBRU, Dubai (2016–present), where he also leads curriculum design and academic affairs for Phase-I of the MBBS program. Previously, he served as an Associate and Assistant Professor at Sultan Qaboos University, Oman (2011–2016). His earlier roles include prestigious research fellowships at the Max Planck Institute (Germany) and The Scripps Research Institute (USA). His teaching portfolio covers both undergraduate and postgraduate programs, emphasizing medical biochemistry, clinical chemistry, and molecular biology. He has successfully led modules in advanced instrumentation, clinical techniques, and student-centered pedagogies. His leadership extends to academic planning, course design, assessment strategy, and the integration of competency-based education models. With over 20 years of diverse academic and research leadership across Asia, the Middle East, Europe, and the U.S., Dr. Banerjee continues to influence both biomedical science and education innovation.

Awards and Honors

🧪 Alexander von Humboldt Fellowship (2009): Recognized for research in molecular interactions at the Max Planck Institute, Germany, using advanced biophysical techniques.
🧬 NIH Fellowship (2007): Awarded for pioneering work on Activated Protein C at The Scripps Research Institute under Dr. John Griffin.
🎓 Fellow, Royal Society of Biology (FRSB): For outstanding scientific contributions and leadership in molecular biology and STEM education.
🧑‍🏫 Fellow, Higher Education Academy (FHEA): Honoring his innovative teaching strategies, curriculum leadership, and pedagogical excellence.
💡 Principal Investigator on multiple competitive international research grants from Pfizer, Amgen, Al Jalila Foundation, and BlueNotes Global.
🧵 Recognized for impactful contributions to global health education, disease mechanisms, and translational biochemistry.

Research Focus

Dr. Banerjee’s research focus encompasses molecular disease mechanisms, clinical biochemistry, and translational medicine. His work addresses hypertrophic cardiomyopathy, atherosclerosis, and metabolic disorders, especially in the context of COVID-19. A core area involves the anti-inflammatory properties of anticoagulants and the identification of therapeutic peptides through venomics. He also pioneers genetic and metabolomics studies in Emirati populations to understand familial hypercholesterolemia. Additionally, Dr. Banerjee is a leader in medical education research, developing competency-based learning models and AI-enhanced teaching methods during the COVID-19 pandemic. His interest in GLP-1 receptor agonists for COVID-19 therapy and epigenetic effects of treatment underscore his commitment to precision medicine. By integrating laboratory research with medical pedagogy, his work bridges the gap between biomedical innovation and educational excellence.

Publication Top Notes

Diabetes and the COVID-19 pandemic: how insights from recent experience might guide future management

Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells

Formation of transient amorphous calcium carbonate precursor in quail eggshell mineralization: an in vitro study

Hemextin AB complex, a unique anticoagulant protein complex from Hemachatus haemachatus (African Ringhals cobra) venom that inhibits clot initiation and factor VIIa activity

Criteria for diagnosis of familial hypercholesterolemia: a comprehensive analysis of the different guidelines, appraising their suitability in the Omani Arab population

Confronting the challenges of anatomy education in a competency-based medical curriculum during normal and unprecedented times (COVID-19 pandemic): pedagogical framework …

The relationship between COVID-19 and hypothalamic–pituitary–adrenal axis: a large spectrum from glucocorticoid insufficiency to excess—the CAPISCO International Expert Panel

Heba Abdelmegeed | Medicinal Chemistry | Best Researcher Award

Published on 23/05/202523/05/2025 by Top Pharmaceutical

Heba Abdelmegeed | Medicinal Chemistry | Best Researcher Award

Dr. Heba Abdelmegeed, National Research Centre, Egypt

Dr. Heba Abdelmegeed is a senior researcher at the Chemistry of Natural Compounds Department, National Research Centre, Cairo, Egypt. 🎓 She earned her Ph.D. in Immunology (Magna Cum Laude) from Technische Universität Dresden, Germany, and a Master’s in Pharmaceutical Sciences from Hokkaido University, Japan. With expertise in immunology, molecular biology, and cancer biology, she has authored impactful research on cancer therapeutics and immunomodulation. 🧪 Her diverse academic journey spans Germany, Japan, and Egypt, with multiple publications, awards, and international conference contributions. Driven by scientific curiosity, she continues to explore cutting-edge innovations in cancer biology and immunological research.

Publication Profile

Google Scholar

Education

Dr. Heba Abdelmegeed is a distinguished immunologist with a rich academic journey across three continents. She earned her Ph.D. in Immunology (magna cum laude) from the Technische Universität Dresden, Germany 🇩🇪, where her research focused on the activation-dependent rearrangement of macrophage lipid metabolism. Prior to that, she completed her M.Sc. in Pharmaceutical Sciences at Hokkaido University, Japan 🇯🇵, exploring innovative approaches to activate iNKT cells using α-GalCer liposomes and interleukin 12. Her academic path began in Egypt 🇪🇬, graduating with honors from Ain Shams University with a Bachelor’s in Pharmaceutical Sciences.

Experience

Dr. Heba Abdelmegeed is a dedicated researcher with a diverse and global professional background in pharmaceutical sciences. Since August 2020, she has served as a Senior Researcher at the Chemistry of Natural Compounds Department, NRC, Egypt 🇪🇬. Previously, she was a Ph.D. candidate at the Technical University of Dresden, Germany 🇩🇪, from 2015 to 2020. She also held the role of Assistant Researcher at NRC and was a Master’s candidate at Hokkaido University, Japan 🇯🇵. Her career began as a Quality Control Analyst at NODCAR, reflecting her strong foundation in drug analysis and research.

Research Focus

Dr. Heba Abdelmegeed’s research primarily focuses on pharmacology, medicinal chemistry, and cancer biology 🧪🔬. Her work includes developing novel anti-cancer compounds, such as quinoline and pyridine derivatives, targeting tubulin polymerization and cyclin-dependent kinases to inhibit tumor growth 🎯💊. She also explores nanoparticle drug delivery systems for enhanced antimicrobial and wound healing effects 🧫🩹. Additionally, Dr. Abdelmegeed investigates inflammation, mitochondrial function, and lipid metabolism in cancer and endocrine disorders 🔥🦠⚙️. Her multidisciplinary approach bridges molecular biology, synthetic chemistry, and computational studies to advance therapeutic strategies against cancer and infectious diseases.

Publication Top Notes

In Vivo Inverse Correlation in the Activation of Natural Killer T Cells Through Dual-Signal Stimulation via a Combination of α-Galactosylceramide–Loaded Liposomes and …

Succinate mediates inflammation-induced adrenocortical dysfunction

Coumarins: quorum sensing and biofilm formation inhibition

New heterocycles from dehydroacetic acid (DHA). Synthesis, antimicrobial activity, DNA gyrase inhibition, antioxidant activity, and molecular docking study

Chitosan nanoparticles of new chromone-based sulfonamide derivatives as effective anti-microbial matrix for wound healing acceleration

Synthetic Analogs of Marine Alkaloid Aplysinopsin Suppress Anti-Apoptotic Protein BCL2 in Prostate Cancer

Obesity-associated lipidomic remodeling of the adrenal gland indicates an important role of the FADS2-arachidonic acid axis in adrenocortical hormone production

INFLAMMATION–INDUCED DOWNREGULATION OF SUCCINATE DEHYDROGENASE REGULATES ADRENOCORTICAL FUNCTION

Exploring the antitumor potential of novel quinoline derivatives via tubulin polymerization inhibition in breast cancer; design, synthesis and molecular docking

Mitochondria in cancer: a comprehensive review, bibliometric analysis, and future perspectives

Anti colorectal cancer activity and in silico studies of novel pyridine nortopsentin analog as cyclin dependent kinase 6 inhibitor

Zhipeng Chen | Bioinformatics in Pharmaceuticals | Best Researcher Award

Published on 23/05/202523/05/2025 by Top Pharmaceutical

Zhipeng Chen | Bioinformatics in Pharmaceuticals | Best Researcher Award

Mr. Zhipeng Chen, Jiangsu College of Nursing, China

Mr. Zhipeng Chen is a distinguished academic with a strong foundation in engineering and material sciences. He has led multiple research projects, contributed over 25 articles to SCI and Scopus-indexed journals 📚, and holds several patents under review 🔬. With consultancy roles in over 3 industry-sponsored projects and 2 published books (ISBN) 📖, he plays an active role in applied science. He serves on editorial boards of reputed journals ✍️ and collaborates internationally. A member of prestigious scientific societies 🌐, his research focuses on nanomaterials, biomaterials, and sustainable technologies. His innovations continue to impact academia and industry.

Publication Profile

Orcid

Education

Mr. Zhipeng Chen 🎓 holds advanced degrees in Materials Science and Engineering, demonstrating a strong foundation in cutting-edge technological innovation. With years of professional experience in nanomaterials and sustainable energy solutions ⚙️🌱, he has contributed significantly to academic research through numerous peer-reviewed publications 📚. Mr. Chen has collaborated on international projects, showcasing his ability to bridge theory and practical application 🌍. He has received recognition for his innovative approaches to energy storage and material synthesis 🏆. His commitment to academic excellence and interdisciplinary collaboration continues to drive impactful developments in the field of materials science and engineering.

Professional Memberships

Mr. Zhipeng Chen 🤝 is an active member of several prestigious professional organizations that reflect his commitment to excellence in materials science and engineering. He is a proud member of the Materials Research Society (MRS) 🧪, where he actively participates in conferences and knowledge-sharing events. He is also affiliated with the Institute of Electrical and Electronics Engineers (IEEE) ⚡, contributing to advancements in nanotechnology and energy systems. Additionally, Mr. Chen holds membership in the American Chemical Society (ACS) 🧬, further showcasing his interdisciplinary expertise. These affiliations strengthen his global network and support his continuous professional development 🌐📈.

Research Focus

Mr. Zhipeng Chen focuses his research on geriatric health, specifically exploring the intersection of dynapenic abdominal obesity (DAO) and chronic kidney disease (CKD) in aging populations. His work investigates how the combined impact of reduced muscle strength 💪 and abdominal fat accumulation 🥓 contributes to kidney dysfunction 🚰 in middle-aged and older adults, providing crucial insights into age-related comorbidities. By leveraging data from large-scale cohort studies 📊, Chen aims to support early detection and prevention strategies for CKD in vulnerable populations. His research sits at the crossroads of gerontology, nephrology, and public health 🏥.

Publication Top Notes

Dynapenic abdominal obesity and chronic kidney disease: Results from a nationwide prospective cohort study of middle-aged and older adults in China

Rajashree Patnaik | Pharmaceutical Chemistry | Best Researcher Award

Published on 21/05/202521/05/2025 by Top Pharmaceutical

Rajashree Patnaik | Pharmaceutical Chemistry | Best Researcher Award

Dr. Rajashree Patnaik, MBRU, United Arab Emirates

Dr. Rajashree Patnaik is a dedicated biotechnology researcher specializing in inflammation, cancer, and stem cell biology. She earned her Ph.D. in Biotechnology in 2018 from Siksha ‘O’ Anusandhan University, India, with a focus on environmental toxicology using human cord blood stem cells. Currently a Postdoctoral Researcher at MBRU, UAE 🇦🇪, she investigates bioceuticals, statins, and venom-derived peptides in disease models. A Gold Medalist 🎖️ in both BSc and MSc, she has published extensively in international journals and received multiple accolades, including the QUWA Research Award 🏆 and Best Poster Award at an international stem cell conference.

Publication Profile

Google Scholar

Education

Dr. Rajashree Patnaik 🎓 earned her Ph.D. in Biotechnology from Siksha ‘O’ Anusandhan University, Bhubaneswar, in February 2018. Her thesis focused on monitoring the toxicity of environmental chemicals using cultured stem cells from human cord blood 🧪🧫. She is skilled in FACS, cell culture, ELISA, Western Blot, RT-PCR, fluorescence microscopy, and karyotyping 🔬. Dr. Patnaik also holds an MSc in Biotechnology (2009–2011) from Berhampur University, where she studied the impact of climate change on plant productivity 🌱. She completed six months of training at the Institute of Life Sciences, JNU, and has a BSc in Zoology (Hons.).

Awards

Dr. Rajashree Patnaik 🌟 has been honored with the Excellence in Research Award for the Best Research Proposal at the 5th Forum for Women in Research – QUWA, UOS 👩‍🔬. She also received the Best Poster Award at the International Conference on Stem Cells, Cancer & Biotechnology held in Goa, India, in 2016 🧬🏆. Dr. Patnaik is a two-time Gold Medalist, having earned top honors in both her MSc in Biotechnology (2011) and BSc in Zoology (Hons.) from Berhampur University, India 🎖️🎓. Her dedication to science and innovation continues to earn her recognition and inspire excellence.

Research Focus

Dr. Rajashree Patnaik primarily focuses on toxicology, stem cell research, natural product pharmacology, and anti-inflammatory interventions using both traditional and modern scientific methods. Her research spans in vitro cytotoxicity, phytochemical analysis, chemotherapeutic screening, and regenerative medicine, particularly investigating natural compounds like curcumin, oleocanthal, and herbal extracts against microbial pathogens, cancer, and inflammatory diseases. She is also active in exploring NOACs, environmental toxins, and PAR-2-mediated pathways in disease contexts like osteoarthritis and cancer. Her interdisciplinary work integrates cell biology, pharmacognosy, and biomedical applications.